Project Grant R01EB036091
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is supporting research to develop a biomolecular-based technology that can locally deliver photocurrents to cardiomyocytes. The $350,112 project, running from August 1, 2025 to July 31, 2027, aims to create free-standing nanostructures that are photocurrent-generating and cell-interacting, serving as phototransducer cardiac biomaterials. The research being conducted at the...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $293,653 to 3DT Holdings, LLC to develop a software tool for optimizing cardiac resynchronization therapy (CRT), conduction system pacing (CSP), and left ventricular endocardial pacing (LVEP) therapies. The goal is to reduce non-responder rates and improve patient identification for these treatments, especially for patients with...
- This federal Project Grant award from the National Science Foundation's Engineering program (CFDA 47.041) provides $630,000 to the University of Chicago to develop a new technology called the Monolithic Adjustable Photostimulation (MAP) platform for high spatiotemporal photostimulation of the nervous system. The project aims to create minimally-invasive, optically-controlled neuromodulation devices using advanced silicon heterojunctions that can precisely stimulate neural circuits, with the goal...
- This Project Grant award from the National Science Foundation (NSF) under the Engineering program (CFDA 47.041) provides $199,992 to Boston University to develop a high-throughput electrical stimulation screening platform for assessing the long-term effects of cardiac contractility modulation (CCM) devices on engineered human heart tissue. The project will support a postdoctoral scholar co-mentored by researchers at the Food and Drug Administration (FDA) and Boston University to advance...
- This federal Project Grant award of $313,302.00, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a novel lead delivery platform for precise cardiac conduction system pacing. The key products and services to be delivered include a 3D pre-shaped delivery catheter with features to enable physicians to monitor pacing parameters, implant depth, and cardiac conduction system capture during the implantation...
- This $323,230 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a multi-channel radiofrequency and pulsed field energy source generator for cardiac ablation procedures. The award recipient, Sirona Medical Technologies, Inc., is developing a novel catheter device and customizable energy generator to improve the safety and precision of cardiac ablation treatments. Key product features include...
- This $437,461 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), funded under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel stabilization catheter device for His pacing lead implantation. The goal is to improve the accuracy and ease of His bundle pacing, an emerging alternative cardiac resynchronization therapy (CRT) for heart failure patients. The project aims to refine a deployable suction-tipped lead...
- The federal Project Grant award, funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a real-time, continuous monitoring platform to track cardiac troponin I (cTnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels alongside electrocardiogram (ECG) readings. The $127,926 award to The Leland Stanford Junior University...
- This $390,000 National Science Foundation project grant supports the development of novel biophotonic computing devices through the Engineering Directorate's 47.041 Engineering program. Specifically, the principal investigator aims to create a flexible, sustainable platform for bio-photonic thin film transistors using cellulose-nanocrystals with chiral nematic organization and responsive photonic behavior. Over the two-year period from September 15, 2022 to August 31, 2025, the grantee,...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $732,221 to The Johns Hopkins University to evaluate the clinical feasibility and safety of an mRNA-based biological pacemaker approach. The goal is to develop an alternative to implantable cardiac pacemakers by reprogramming ventricular myocytes to function as pacemaker cells, creating de novo cardiac pacing in vivo. The 4-year...
MULTI-SITE PHOTOSTIMULATION DEVICES USING POROSITY-BASED SEMICONDUCTOR HETEROJUNCTIONS FOR CARDIAC RESYNCHRONIZATION THERAPY - PROJECT SUMMARY IN CARDIOVASCULAR DISEASE DIAGNOSIS, TREATMENT, AND MONITORING, A PLETHORA OF DEFORMABLE BIOINTERFACE DEVICES ARE UTILIZED. THESE DEVICES ARE ADEPT AT GAUGING PHYSIOLOGICAL METRICS, ADMINISTERING BIOELECTRICAL MODULATION, OR DISPENSING THERAPEUTICS. NOTWITHSTANDING THE ADVENT OF PRECLINICAL BIOTECHNOLOGIES LIKE OPTOGENETICS AND CELL-BASED BIOLOGICAL PACING, NON-GENETIC ELECTRONIC PACING PERSISTS AS THE PREDOMINANT THERAPEUTIC APPROACH FOR CARDIAC RHYTHM ANOMALIES. RECENTLY, SEMICONDUCTORS HAVE BEEN IDENTIFIED AS PROMISING INSTRUMENTS FOR NON-GENETIC CARDIOVASCULAR INVESTIGATIONS. OUR TEAM IS FOCUSING ON DESIGNING MINIMALLY INVASIVE PHOTOSTIMULATION TOOLS SPECIFICALLY TAILORED FOR CARDIAC PACING APPLICATIONS. WE RECENTLY PUBLISHED SEVERAL PHOTOELECTROCHEMICAL METHODS FOR OPTICALLY MODULATING CARDIAC ACTIVITY IN CULTURED CELLS AND ADULT RODENT MODELS EX VIVO. USING THESE METHODS, WE CAN ACHIEVE LIGHT-ACTIVATED MODULATION OF CARDIAC TISSUE WITH A LIGHT INTENSITY COMPARABLE TO THAT USED IN OPTOGENETICS. IN THIS CURRENT WORK, TIAN, HIBINO, JIA AND AZIZ WILL WORK TOGETHER TO EXPAND AND STRENGTHEN OUR NEWEST PHOTOSTIMULATION SYSTEM, POROSITY-BASED SILICON HETEROJUNCTIONS, FOR MULTI-SITE, LEADLESS, NONGENETIC, AND OPTOELECTRONIC MODULATION OF CARDIAC TISSUES. SPECIFICALLY, OUR TEAM AIMS TO DESIGN, FABRICATE, AND EVALUATE A RANGE OF POROSITY-BASED HETEROJUNCTIONS TAILORED FOR OPTICAL MODULATION OF CARDIAC TISSUES. WE WILL SYNTHESIZE SILICON MEMBRANES WITH NON- POROUS/NANOPOROUS HETEROJUNCTIONS AND THREE-DIMENSIONAL SURFACE TOPOGRAPHIES. TO ENHANCE THE STABILITY OF THESE HETEROJUNCTIONS AND MODULATE THEIR LONGEVITY UNDER PHYSIOLOGICAL CONDITIONS, WE WILL EMPLOY ATOMIC LAYER DEPOSITION TO PASSIVATE THE SILICON INTERFACES. WE PLAN TO MODIFY THE SURFACE WITH METAL OR METAL-OXIDE CATALYSTS TO BOLSTER SIGNAL TRANSDUCTION. TO SUPPORT THE SILICON HETEROJUNCTIONS, WE WILL INTEGRATE SOFT MATRICES, INCLUDING POLYMERS AND HYDROGELS, ENHANCING BOTH BIOCOMPATIBILITY AND SIGNAL TRANSDUCTION AT BIOINTERFACES. CONCURRENTLY, WE WILL PRODUCE BIOCOMPATIBLE, STRETCHABLE OPTICAL FIBERS TAILORED FOR IN VIVO PHOTOSTIMULATION. OUR TEAM IS ALSO DEVELOPING A CATHETER-ANALOGOUS MINIMALLY INVASIVE PHOTOSTIMULATION TOOL. FOR MULTI-SITE OPTICAL PACING, WE WILL ENGINEER AND ASSESS THE REQUISITE SOFTWARE, MECHANICAL, ELECTRICAL, AND OPTICAL SUBSYSTEMS. WE WILL VALIDATE THE PERFORMANCE METRICS OF OUR RANDOM ACCESS PHOTOSTIMULATION TOOLS, INCLUDING ACCURACY, SCANNING VELOCITY, AND POWER DELIVERY, FOLLOWED BY EX VIVO PHOTOSTIMULATION TRIALS. IN VIVO BIOCOMPATIBILITY ASSESSMENTS WILL BE CONDUCTED IN A RAT MODEL, WHILE WE WILL GAUGE HEART PACING EFFICACY IN ACUTE AND CHRONIC SCENARIOS USING SINGLE-CHAMBER, DUAL-CHAMBER, AND MULTI-SITE STIMULATIONS IN A PIG MODEL. WE WILL TEST OUR HYPOTHESIS THAT DEFORMABLE AND BIOCOMPATIBLE HETEROJUNCTION DEVICES CAN BE USED FOR MULTI-SITE CARDIAC RESYNCHRONIZATION THERAPY. THE NEW DESIGNS FOR SEMICONDUCTOR-BASED BIOINTERFACES WILL ALLOW FOR MINIMALLY-INVASIVE, WIRELESS, NONGENETIC, MULTISCALE, AND RANDOM ACCESS PHOTOSTIMULATION.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $588.2k | 7/23/25 | ||
| Not listed | $606.6k | 7/3/24 |